Verdien av nye legemidler: om betydningen av prisfall etter innføring for vurdering av nye legemidler i Norge

Report number:
Title: Verdien av nye legemidler: om betydningen av prisfall etter innføring for vurdering av nye legemidler i Norge
Client: Legemiddelindustrien (LMI)
Published:
Link: PDF

See all publications

Newest articles

ISPOR Europe 2026

Oslo Economics is attending ISPOR 2026 to share insights and engage in discussions on health economics and policy. Learn more about our participation here.

What should Northern Norway’s future flight network look like?

In autumn 2028, the current contracts for publicly subsidised air routes in Northern Norway will expire. Commissioned by the Norwegian […]

The Norwegian Competition Authority Approves Elkjøp’s Acquisition of Eplehuset

On 29 June, the Norwegian Competition Authority (NCA) issued a Statement of Objection (SO) against Elkjøp’s proposed acquisition of Eplehuset. On 31 July, however, the […]

Verdien av nye legemidler: om betydningen av prisfall etter innføring for vurdering av nye legemidler i Norge

ISPOR Europe 2026

What should Northern Norway’s future flight network look like?

The Norwegian Competition Authority Approves Elkjøp’s Acquisition of Eplehuset

Bergen

Oslo

Berlin